Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Dianthus Therapeutics Inc. (NASDAQ:DNTH) released topline data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG).

Claseprubart 300mg and 600mg demonstrated rapid, statistically significant, and clinically meaningful improvements over placebo as measured by both MG-ADL and QMG, including at Week 1 and at Week 13.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.